Hims & Hers Health (HIMS) has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable profitability ...

Hims & Hers Health stock is trading -39.24% below its average target price of $44.82 after marking a 1.0% during today's ...

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Trial data data showed Lilly's experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer ...

Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to ...